No association was observed between serious infection risk and Janus kinase inhibitor use in patients with immune-mediated inflammatory skin disease.

The off-label use of JAK inhibitors to treat JDM is common in pediatric rheumatology, with barriers to use including limited clinical trial data and insurance approval.

Only half of patients showed clinical improvement attributed to the medication, but only one new complication occurred.

JAK inhibitors, such as ruxolitinib cream and abrocitinib, present promising alternatives to existing therapies for managing moderate to severe atopic dermatitis, offering effective treatment options.

Janus kinase (JAK) inhibitors are associated with an increased risk for lung cancer but not overall cancer among older patients in the United States with rheumatoid arthritis (RA), according to study ...

In addition to a greater risk for serious infection, patients with atopic dermatitis initiating JAK inhibitors vs Th2 cytokine inhibitors had a greater risk of Candida infections and a slightly ...

Panelists discuss how treatment selection among Janus kinase (JAK) inhibitors for myelofibrosis involves considering specific ...

A prospective registry study found a greater risk for infections associated with JAK inhibitors in adolescents and adults with moderate to severe atopic dermatitis compared with biologics.

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Concerns have arisen over JAK inhibitors' cardiovascular safety relative to TNF inhibitors and other biologic agents ...

"We see a number of examples with the IL-23 inhibitors that ... Currently approved therapies for alopecia areata are all JAK inhibitors and carry boxed warning labels, King noted.